Comparison effect of melatonin and zinc in optimization of sleep disorder in cirrhotic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121021011192N18

Enrollment

Registered

2024-07-20

Start date

2024-08-22

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with diagnosis of cirrhosis. Unspecified cirrhosis of liver

Interventions

Intervention 1: Intervention group 1: Addition of melatonin tablet 5mg nightly to pharmacologic regimen for 4 weeks. Intervention 2: Intervention group 2: Addition of zinc tablet 30 mg nightly to pha

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with diagnosis of cirrhosis on the basis of doing liver biopsy obtaining written informed consent

Exclusion criteria

Exclusion criteria: Patients with previous history of allergy to melatonin or zinc

Design outcomes

Primary

Measure	Time frame
Assessment of sleep in cirrhotic patienr. Timepoint: 4 weeks after starting the treatment. Method of measurement: Pittsburg questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Abbasinazari

Shahid Beheshti University of Medical Sciences

m_abbasi@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026